Abstract

Diffuse infiltration is the main reason for therapeutic resistance and recurrence in glioblastoma (GBM). However, potential targeted therapies for GBM stem-like cell (GSC) which is responsible for GBM invasion are limited. Herein, we report Insulin-like Growth Factor-Binding Protein 5 (IGFBP5) is a ligand for Receptor tyrosine kinase like Orphan Receptor 1 (ROR1), as a promising target for GSC invasion. Using a GSC-derived brain tumor model, GSCs were characterized into invasive or non-invasive subtypes, and RNA sequencing analysis revealed that IGFBP5 was differentially expressed between these two subtypes. GSC invasion capacity was inhibited by IGFBP5 knockdown and enhanced by IGFBP5 overexpression both in vitro and in vivo, particularly in a patient-derived xenograft model. IGFBP5 binds to ROR1 and facilitates ROR1/HER2 heterodimer formation, followed by inducing CREB-mediated ETV5 and FBXW9 expression, thereby promoting GSC invasion and tumorigenesis. Importantly, using a tumor-specific targeting and penetrating nanocapsule-mediated delivery of CRISPR/Cas9-based IGFBP5 gene editing significantly suppressed GSC invasion and downstream gene expression, and prolonged the survival of orthotopic tumor-bearing mice. Collectively, our data reveal that IGFBP5-ROR1/HER2-CREB signaling axis as a potential GBM therapeutic target.

Glioblastoma stem-like cells (GSCs) contribute to therapeutic resistance and recurrence of glioblastomas. Here the authors show that Insulin-like Growth Factor-Binding Protein 5 (IGFBP5) is a ligand for Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) promotes GSCs invasion.

Details

Title
IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis
Author
Lin, Weiwei 1 ; Niu, Rui 2 ; Park, Seong-Min 3 ; Zou, Yan 4   VIAFID ORCID Logo  ; Kim, Sung Soo 5   VIAFID ORCID Logo  ; Xia, Xue 2 ; Xing, Songge 2 ; Yang, Qingshan 2 ; Sun, Xinhong 2 ; Yuan, Zheng 2 ; Zhou, Shuchang 2 ; Zhang, Dongya 2 ; Kwon, Hyung Joon 6 ; Park, Saewhan 5 ; Il Kim, Chan 5   VIAFID ORCID Logo  ; Koo, Harim 5 ; Liu, Yang 2 ; Wu, Haigang 2 ; Zheng, Meng 2 ; Yoo, Heon 7 ; Shi, Bingyang 4   VIAFID ORCID Logo  ; Park, Jong Bae 8   VIAFID ORCID Logo  ; Yin, Jinlong 9   VIAFID ORCID Logo 

 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X); National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); National Cancer Center, Research Institute, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); Ewha Womans University, Department of Life Science, Seoul, Republic of Korea (GRID:grid.255649.9) (ISNI:0000 0001 2171 7754) 
 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X) 
 National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); Personalized Genomic Medicine Research Center, KRIBB, Daejeon, Republic of Korea (GRID:grid.249967.7) (ISNI:0000 0004 0636 3099) 
 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X); Macquarie University, Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine & Health Sciences, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405) 
 National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810) 
 National Cancer Center, Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810) 
 National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); National Cancer Center, Research Institute, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810) 
 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X); National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); National Cancer Center, Research Institute, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810) 
 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X); National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810) 
Pages
1578
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2789592916
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.